Leptin	B:C0385463
receptor	I:C0385463
antagonism	O
of	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
function	I:C0007613
:	O
a	O
novel	O
strategy	O
to	O
combat	O
multiple	O
myeloma	I:C0026764
.	O

Leptin	O
receptor	I:C0385463
antagonism	B:C0007613
of	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
function	I:C0007613
:	O
a	O
novel	O
strategy	O
to	O
combat	O
multiple	O
myeloma	I:C0026764
.	O

Leptin	O
receptor	I:C0385463
antagonism	O
of	O
invariant	B:C2350467
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
function	I:C0007613
:	O
a	O
novel	O
strategy	O
to	O
combat	O
multiple	O
myeloma	I:C0026764
.	O

Leptin	O
receptor	I:C0385463
antagonism	O
of	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	B:C0007613
function	I:C0007613
:	O
a	O
novel	O
strategy	O
to	O
combat	O
multiple	O
myeloma	I:C0026764
.	O

Leptin	O
receptor	I:C0385463
antagonism	O
of	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
function	I:C0007613
:	O
a	O
novel	O
strategy	O
to	O
combat	O
multiple	B:C0026764
myeloma	I:C0026764
.	O

A	O
hallmark	O
of	O
bone	B:C0005953
marrow	I:C0005953
changes	O
with	O
aging	O
is	O
the	O
increase	O
in	O
adipocyte	O
composition	O
,	O
but	O
how	O
this	O
impacts	O
development	O
of	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
is	O
unknown	O
.	O

A	O
hallmark	O
of	O
bone	O
marrow	I:C0005953
changes	O
with	O
aging	B:C0001811
is	O
the	O
increase	O
in	O
adipocyte	O
composition	O
,	O
but	O
how	O
this	O
impacts	O
development	O
of	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
is	O
unknown	O
.	O

A	O
hallmark	O
of	O
bone	O
marrow	I:C0005953
changes	O
with	O
aging	O
is	O
the	O
increase	O
in	O
adipocyte	B:C0206131
composition	O
,	O
but	O
how	O
this	O
impacts	O
development	O
of	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
is	O
unknown	O
.	O

A	O
hallmark	O
of	O
bone	O
marrow	I:C0005953
changes	O
with	O
aging	O
is	O
the	O
increase	O
in	O
adipocyte	O
composition	B:C0486616
,	O
but	O
how	O
this	O
impacts	O
development	O
of	O
multiple	O
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
is	O
unknown	O
.	O

A	O
hallmark	O
of	O
bone	O
marrow	I:C0005953
changes	O
with	O
aging	O
is	O
the	O
increase	O
in	O
adipocyte	O
composition	O
,	O
but	O
how	O
this	O
impacts	O
development	O
of	O
multiple	B:C0026764
myeloma	I:C0026764
(	O
multiple	O
myeloma	I:C0026764
)	O
is	O
unknown	O
.	O

A	O
hallmark	O
of	O
bone	O
marrow	I:C0005953
changes	O
with	O
aging	O
is	O
the	O
increase	O
in	O
adipocyte	O
composition	O
,	O
but	O
how	O
this	O
impacts	O
development	O
of	O
multiple	O
myeloma	I:C0026764
(	O
multiple	B:C0026764
myeloma	I:C0026764
)	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
the	O
role	O
of	O
the	O
adipokine	B:C1955907
leptin	O
as	O
master	O
regulator	O
of	O
anti-	O
myeloma	O
tumor	I:C1519680
immunity	I:C1519680
by	O
modulating	O
the	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
(	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
)	O
cell	O
function	I:C0007613
.	O

Here	O
,	O
we	O
report	O
the	O
role	O
of	O
the	O
adipokine	O
leptin	B:C0299583
as	O
master	O
regulator	O
of	O
anti-	O
myeloma	O
tumor	I:C1519680
immunity	I:C1519680
by	O
modulating	O
the	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
(	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
)	O
cell	O
function	I:C0007613
.	O

Here	O
,	O
we	O
report	O
the	O
role	O
of	O
the	O
adipokine	O
leptin	O
as	O
master	O
regulator	O
of	O
anti-	O
myeloma	B:C1519680
tumor	I:C1519680
immunity	I:C1519680
by	O
modulating	O
the	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
(	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
)	O
cell	O
function	I:C0007613
.	O

Here	O
,	O
we	O
report	O
the	O
role	O
of	O
the	O
adipokine	O
leptin	O
as	O
master	O
regulator	O
of	O
anti-	O
myeloma	O
tumor	I:C1519680
immunity	I:C1519680
by	O
modulating	O
the	O
invariant	B:C2350467
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
(	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
)	O
cell	O
function	I:C0007613
.	O

Here	O
,	O
we	O
report	O
the	O
role	O
of	O
the	O
adipokine	O
leptin	O
as	O
master	O
regulator	O
of	O
anti-	O
myeloma	O
tumor	I:C1519680
immunity	I:C1519680
by	O
modulating	O
the	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
(	O
invariant	B:C2350467
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
)	O
cell	O
function	I:C0007613
.	O

Here	O
,	O
we	O
report	O
the	O
role	O
of	O
the	O
adipokine	O
leptin	O
as	O
master	O
regulator	O
of	O
anti-	O
myeloma	O
tumor	I:C1519680
immunity	I:C1519680
by	O
modulating	O
the	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
(	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
)	O
cell	B:C0007613
function	I:C0007613
.	O

A	O
marked	O
increase	B:C2747815
in	I:C2747815
serum	I:C2747815
leptin	I:C2747815
levels	I:C2747815
and	O
leptin	O
receptor	I:C0385463
(	O
leptin	O
receptor	I:C0385463
)	O
expression	O
on	O
iNKT	O
cells	I:C2350467
in	O
multiple	O
myeloma	I:C0026764
patients	O
and	O
the	O
5T33	O
murine	O
multiple	O
myeloma	I:C0026764
model	O
was	O
observed	O
.	O

A	O
marked	O
increase	O
in	I:C2747815
serum	I:C2747815
leptin	I:C2747815
levels	I:C2747815
and	O
leptin	B:C0385463
receptor	I:C0385463
(	O
leptin	O
receptor	I:C0385463
)	O
expression	O
on	O
iNKT	O
cells	I:C2350467
in	O
multiple	O
myeloma	I:C0026764
patients	O
and	O
the	O
5T33	O
murine	O
multiple	O
myeloma	I:C0026764
model	O
was	O
observed	O
.	O

A	O
marked	O
increase	O
in	I:C2747815
serum	I:C2747815
leptin	I:C2747815
levels	I:C2747815
and	O
leptin	O
receptor	I:C0385463
(	O
leptin	B:C0385463
receptor	I:C0385463
)	O
expression	O
on	O
iNKT	O
cells	I:C2350467
in	O
multiple	O
myeloma	I:C0026764
patients	O
and	O
the	O
5T33	O
murine	O
multiple	O
myeloma	I:C0026764
model	O
was	O
observed	O
.	O

A	O
marked	O
increase	O
in	I:C2747815
serum	I:C2747815
leptin	I:C2747815
levels	I:C2747815
and	O
leptin	O
receptor	I:C0385463
(	O
leptin	O
receptor	I:C0385463
)	O
expression	O
on	O
iNKT	B:C2350467
cells	I:C2350467
in	O
multiple	O
myeloma	I:C0026764
patients	O
and	O
the	O
5T33	O
murine	O
multiple	O
myeloma	I:C0026764
model	O
was	O
observed	O
.	O

A	O
marked	O
increase	O
in	I:C2747815
serum	I:C2747815
leptin	I:C2747815
levels	I:C2747815
and	O
leptin	O
receptor	I:C0385463
(	O
leptin	O
receptor	I:C0385463
)	O
expression	O
on	O
iNKT	O
cells	I:C2350467
in	O
multiple	B:C0026764
myeloma	I:C0026764
patients	O
and	O
the	O
5T33	O
murine	O
multiple	O
myeloma	I:C0026764
model	O
was	O
observed	O
.	O

A	O
marked	O
increase	O
in	I:C2747815
serum	I:C2747815
leptin	I:C2747815
levels	I:C2747815
and	O
leptin	O
receptor	I:C0385463
(	O
leptin	O
receptor	I:C0385463
)	O
expression	O
on	O
iNKT	O
cells	I:C2350467
in	O
multiple	O
myeloma	I:C0026764
patients	O
and	O
the	O
5T33	O
murine	B:C0591833
multiple	O
myeloma	I:C0026764
model	O
was	O
observed	O
.	O

A	O
marked	O
increase	O
in	I:C2747815
serum	I:C2747815
leptin	I:C2747815
levels	I:C2747815
and	O
leptin	O
receptor	I:C0385463
(	O
leptin	O
receptor	I:C0385463
)	O
expression	O
on	O
iNKT	O
cells	I:C2350467
in	O
multiple	O
myeloma	I:C0026764
patients	O
and	O
the	O
5T33	O
murine	O
multiple	B:C0026764
myeloma	I:C0026764
model	O
was	O
observed	O
.	O

A	O
marked	O
increase	O
in	I:C2747815
serum	I:C2747815
leptin	I:C2747815
levels	I:C2747815
and	O
leptin	O
receptor	I:C0385463
(	O
leptin	O
receptor	I:C0385463
)	O
expression	O
on	O
iNKT	O
cells	I:C2350467
in	O
multiple	O
myeloma	I:C0026764
patients	O
and	O
the	O
5T33	O
murine	O
multiple	O
myeloma	I:C0026764
model	B:C0012644
was	O
observed	O
.	O

multiple	B:C0026764
myeloma	I:C0026764
cells	O
and	O
leptin	O
synergistically	O
counteracted	O
anti-tumor	O
functionality	I:C1516031
of	O
both	O
murine	O
and	O
human	O
iNKT	O
cells	I:C2350467
.	O

multiple	O
myeloma	I:C0026764
cells	B:C0007634
and	O
leptin	O
synergistically	O
counteracted	O
anti-tumor	O
functionality	I:C1516031
of	O
both	O
murine	O
and	O
human	O
iNKT	O
cells	I:C2350467
.	O

multiple	O
myeloma	I:C0026764
cells	O
and	O
leptin	B:C0299583
synergistically	O
counteracted	O
anti-tumor	O
functionality	I:C1516031
of	O
both	O
murine	O
and	O
human	O
iNKT	O
cells	I:C2350467
.	O

multiple	O
myeloma	I:C0026764
cells	O
and	O
leptin	O
synergistically	O
counteracted	O
anti-tumor	B:C1516031
functionality	I:C1516031
of	O
both	O
murine	O
and	O
human	O
iNKT	O
cells	I:C2350467
.	O

multiple	O
myeloma	I:C0026764
cells	O
and	O
leptin	O
synergistically	O
counteracted	O
anti-tumor	O
functionality	I:C1516031
of	O
both	O
murine	B:C0591833
and	O
human	O
iNKT	O
cells	I:C2350467
.	O

multiple	O
myeloma	I:C0026764
cells	O
and	O
leptin	O
synergistically	O
counteracted	O
anti-tumor	O
functionality	I:C1516031
of	O
both	O
murine	O
and	O
human	B:C0086418
iNKT	O
cells	I:C2350467
.	O

multiple	O
myeloma	I:C0026764
cells	O
and	O
leptin	O
synergistically	O
counteracted	O
anti-tumor	O
functionality	I:C1516031
of	O
both	O
murine	O
and	O
human	O
iNKT	B:C2350467
cells	I:C2350467
.	O

In	B:C1515655
vivo	I:C1515655
blockade	O
of	O
leptin	O
receptor	I:C0385463
signalling	O
combined	O
with	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
stimulation	O
resulted	O
in	O
superior	O
anti-tumor	O
protection	I:C1516031
.	O

In	O
vivo	I:C1515655
blockade	O
of	O
leptin	B:C0385463
receptor	I:C0385463
signalling	O
combined	O
with	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
stimulation	O
resulted	O
in	O
superior	O
anti-tumor	O
protection	I:C1516031
.	O

In	O
vivo	I:C1515655
blockade	O
of	O
leptin	O
receptor	I:C0385463
signalling	B:C1514762
combined	O
with	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
stimulation	O
resulted	O
in	O
superior	O
anti-tumor	O
protection	I:C1516031
.	O

In	O
vivo	I:C1515655
blockade	O
of	O
leptin	O
receptor	I:C0385463
signalling	O
combined	O
with	O
invariant	B:C2350467
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
stimulation	O
resulted	O
in	O
superior	O
anti-tumor	O
protection	I:C1516031
.	O

In	O
vivo	I:C1515655
blockade	O
of	O
leptin	O
receptor	I:C0385463
signalling	O
combined	O
with	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
stimulation	B:C1622572
resulted	O
in	O
superior	O
anti-tumor	O
protection	I:C1516031
.	O

In	O
vivo	I:C1515655
blockade	O
of	O
leptin	O
receptor	I:C0385463
signalling	O
combined	O
with	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
stimulation	O
resulted	O
in	O
superior	O
anti-tumor	B:C1516031
protection	I:C1516031
.	O

This	O
was	O
linked	O
to	O
persistent	O
IFN	B:C3156720
-γ	I:C3156720
secretion	I:C3156720
upon	O
repeated	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
stimulation	I:C1622572
and	O
a	O
restoration	O
of	O
the	O
dynamic	O
antigen	O
-	O
induced	O
motility	O
arrest	I:C2259317
as	O
observed	O
by	O
intravital	O
microscopy	I:C0596795
,	O
thereby	O
showing	O
alleviation	O
of	I:C2256009
iNKT	I:C2256009
cell	I:C2256009
anergy	I:C2256009
.	O

This	O
was	O
linked	O
to	O
persistent	O
IFN	O
-γ	I:C3156720
secretion	I:C3156720
upon	O
repeated	O
invariant	B:C2350467
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
stimulation	I:C1622572
and	O
a	O
restoration	O
of	O
the	O
dynamic	O
antigen	O
-	O
induced	O
motility	O
arrest	I:C2259317
as	O
observed	O
by	O
intravital	O
microscopy	I:C0596795
,	O
thereby	O
showing	O
alleviation	O
of	I:C2256009
iNKT	I:C2256009
cell	I:C2256009
anergy	I:C2256009
.	O

This	O
was	O
linked	O
to	O
persistent	O
IFN	O
-γ	I:C3156720
secretion	I:C3156720
upon	O
repeated	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	B:C1622572
stimulation	I:C1622572
and	O
a	O
restoration	O
of	O
the	O
dynamic	O
antigen	O
-	O
induced	O
motility	O
arrest	I:C2259317
as	O
observed	O
by	O
intravital	O
microscopy	I:C0596795
,	O
thereby	O
showing	O
alleviation	O
of	I:C2256009
iNKT	I:C2256009
cell	I:C2256009
anergy	I:C2256009
.	O

This	O
was	O
linked	O
to	O
persistent	O
IFN	O
-γ	I:C3156720
secretion	I:C3156720
upon	O
repeated	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
stimulation	I:C1622572
and	O
a	O
restoration	O
of	O
the	O
dynamic	O
antigen	B:C0003320
-	O
induced	O
motility	O
arrest	I:C2259317
as	O
observed	O
by	O
intravital	O
microscopy	I:C0596795
,	O
thereby	O
showing	O
alleviation	O
of	I:C2256009
iNKT	I:C2256009
cell	I:C2256009
anergy	I:C2256009
.	O

This	O
was	O
linked	O
to	O
persistent	O
IFN	O
-γ	I:C3156720
secretion	I:C3156720
upon	O
repeated	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
stimulation	I:C1622572
and	O
a	O
restoration	O
of	O
the	O
dynamic	O
antigen	O
-	O
induced	O
motility	B:C2259317
arrest	I:C2259317
as	O
observed	O
by	O
intravital	O
microscopy	I:C0596795
,	O
thereby	O
showing	O
alleviation	O
of	I:C2256009
iNKT	I:C2256009
cell	I:C2256009
anergy	I:C2256009
.	O

This	O
was	O
linked	O
to	O
persistent	O
IFN	O
-γ	I:C3156720
secretion	I:C3156720
upon	O
repeated	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
stimulation	I:C1622572
and	O
a	O
restoration	O
of	O
the	O
dynamic	O
antigen	O
-	O
induced	O
motility	O
arrest	I:C2259317
as	O
observed	O
by	O
intravital	B:C0596795
microscopy	I:C0596795
,	O
thereby	O
showing	O
alleviation	O
of	I:C2256009
iNKT	I:C2256009
cell	I:C2256009
anergy	I:C2256009
.	O

This	O
was	O
linked	O
to	O
persistent	O
IFN	O
-γ	I:C3156720
secretion	I:C3156720
upon	O
repeated	O
invariant	O
natural	I:C2350467
killer	I:C2350467
T	I:C2350467
cell	O
stimulation	I:C1622572
and	O
a	O
restoration	O
of	O
the	O
dynamic	O
antigen	O
-	O
induced	O
motility	O
arrest	I:C2259317
as	O
observed	O
by	O
intravital	O
microscopy	I:C0596795
,	O
thereby	O
showing	O
alleviation	B:C2256009
of	I:C2256009
iNKT	I:C2256009
cell	I:C2256009
anergy	I:C2256009
.	O

Overall	O
our	O
data	O
reveal	O
the	O
leptin	B:C0385463
receptor	I:C0385463
axis	O
as	O
novel	O
therapeutic	O
target	O
for	O
checkpoint	O
inhibition	I:C3544497
to	O
treat	O
multiple	O
myeloma	I:C0026764
.	O

Overall	O
our	O
data	O
reveal	O
the	O
leptin	O
receptor	I:C0385463
axis	O
as	O
novel	O
therapeutic	O
target	O
for	O
checkpoint	B:C3544497
inhibition	I:C3544497
to	O
treat	O
multiple	O
myeloma	I:C0026764
.	O

Overall	O
our	O
data	O
reveal	O
the	O
leptin	O
receptor	I:C0385463
axis	O
as	O
novel	O
therapeutic	O
target	O
for	O
checkpoint	O
inhibition	I:C3544497
to	O
treat	O
multiple	B:C0026764
myeloma	I:C0026764
.	O

